Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes
T Yoshimoto, T Furuki, H Kobori… - Journal of …, 2017 - journals.sagepub.com
We conducted a descriptive case study to examine the effects of sodium-glucose cotransporter
2 (SGLT2) inhibitors on urinary angiotensinogen excretion, which represents the function …
2 (SGLT2) inhibitors on urinary angiotensinogen excretion, which represents the function …
Pretreatment body mass index affects achievement of target blood pressure with sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus and …
…, T Kanaoka, H Wakui, H Sakai, T Furuki… - Hypertension …, 2024 - nature.com
Sodium-glucose cotransporter 2 inhibitor (SGLT2-I) shows excellent antihypertensive effects
in addition to its hypoglycemic effects. However, whether body mass index (BMI) affects the …
in addition to its hypoglycemic effects. However, whether body mass index (BMI) affects the …
Cross-sectional survey of hypertension management in clinical practice in Japan: the Kanagawa Hypertension Study 2021 conducted in collaboration with Japan …
K Kobayashi, K Chin, N Hatori, T Furuki, H Sakai… - Hypertension …, 2023 - nature.com
We aim to assess the data of patients with hypertension in Kanagawa Prefecture, Japan,
collected in 2021 that were provided by the Japan Medical Association Database of Clinical …
collected in 2021 that were provided by the Japan Medical Association Database of Clinical …
Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists
…, M Toyoda, N Hatori, H Sakai, T Furuki… - Diabetes Research and …, 2022 - Elsevier
Aims This study aimed to clarify the differences in how sodium glucose co-transporter 2
inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1Ra) influence kidney …
inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1Ra) influence kidney …
[HTML][HTML] Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists
K Kobayashi, M Toyoda, N Hatori, H Sakai, T Furuki… - Scientific Reports, 2022 - nature.com
The cardiovascular and renal protective effects of sodium-glucose cotransporter 2 inhibitors
(SGLT-2is) and glucagon-like peptide 1 receptor agonists (GLP-1Ras) are enhanced by low/…
(SGLT-2is) and glucagon-like peptide 1 receptor agonists (GLP-1Ras) are enhanced by low/…
Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium–Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 …
…, N Saito, T Kanaoka, H Sakai, T Furuki… - Diabetes Technology …, 2021 - liebertpub.com
Aim: Sodium–glucose cotransporter 2 inhibitors (SGLT2is) provide renal protection in
patients with type 2 diabetes mellitus (T2DM). The aim of this study was to elucidate the renal …
patients with type 2 diabetes mellitus (T2DM). The aim of this study was to elucidate the renal …
Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease
…, M Kimura, N Hatori, T Furuki… - Diabetes and …, 2019 - journals.sagepub.com
Aim: The aim of this study was to assess the renal effects of the glucose-lowering SGLT2
inhibitors in Japanese type 2 diabetes mellitus patients with chronic kidney disease. Methods: …
inhibitors in Japanese type 2 diabetes mellitus patients with chronic kidney disease. Methods: …
Sodium–glucose cotransporter 2 inhibitor‐induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients …
…, M Toyoda, N Hatori, T Furuki… - Journal of Diabetes …, 2021 - Wiley Online Library
Aims/Introduction Large‐scale clinical trials have reported that, in patients with type 2 diabetes
mellitus, sodium–glucose cotransporter 2 (SGLT2) inhibitor treatment affords favorable …
mellitus, sodium–glucose cotransporter 2 (SGLT2) inhibitor treatment affords favorable …
[HTML][HTML] Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study
…, T Murata, T Matsushita, T Furuki… - Frontiers in …, 2024 - frontiersin.org
Accumulating evidence has demonstrated that both SGLT2 inhibitors (SGLT2i) and GLP-1
receptor agonists (GLP1Ra) have protective effects in patients with diabetic kidney disease. …
receptor agonists (GLP1Ra) have protective effects in patients with diabetic kidney disease. …
Blood pressure after treatment with sodium–glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score‐matched models
…, M Toyoda, N Hatori, T Furuki… - Journal of Diabetes …, 2021 - Wiley Online Library
Aims/Introduction Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve renal outcome
in patients with type 2 diabetes mellitus, but the mechanism is not fully understood. The …
in patients with type 2 diabetes mellitus, but the mechanism is not fully understood. The …